Polly Newcomb, MD, an epidemiologist at Seattle-based Fred Hutchinson Cancer Research Center, and colleagues conducted an observational study of 2,419 newly diagnosed patients in the Colon Cancer Family Registry.
Researchers divided the patients into groups: patients who took NSAIDs before the diagnosis, patients who took the drugs post-diagnosis, patients who quit using the drugs post-diagnosis and those who did not use the drugs.
Researchers followed up with the patients at a median 10.8 years after diagnosis.
Here’s what you should know:
1. Approximately 42 percent regularly took NSAIDs in both aspirin and nonaspirin forms.
2. Approximately 381 patients died, 100 because of their CRC.
3. Postdiagnostic aspirin-only users have favorable survival and CRC-specific survival scores over nonusers. Patients who initiated aspirin use after diagnosis also had favorable scores.
4. Overall survival rate for patients who used NSAIDs after diagnosis differed through KRAS-mutation status. KRAS-mutations are common in colon cancers.
Patients who used NSAIDs after diagnosis had improved survival rates if they had KRAS wild-type tumors. NSAID use among those with KRAS-mutant tumors showed no improvement.
Researchers concluded, “Among long-term CRC survivors, regular use of NSAIDs after CRC diagnosis was significantly associated with improved survival in individuals with KRAS wild-type tumors.”
More articles on gastroenterology:
Screening colonoscopy complication rates low, study says — 3 notes
Physicians Endoscopy purchases stake in Great South Bay Endoscopy & more: 5 GI practices in the news
GI leader to know: Dr. Ronald Feldman
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
